Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IkT 001Pro

Next Previous
Drug Profile

IkT 001Pro

Alternative Names: IkI 001; IkI-001Pro; IkT-001; IKT-001Pro PML; IKT-001Pro PVAN; Imatinib prodrug

Latest Information Update: 01 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inhibikase Therapeutics
  • Class Amines; Antineoplastics; Antivirals; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive multifocal leukoencephalopathy; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic myeloid leukaemia
  • Preclinical Pulmonary arterial hypertension
  • Discontinued Human polyomavirus infections; Progressive multifocal leukoencephalopathy

Most Recent Events

  • 14 Aug 2025 Inhibikase Therapeutics plans the phase IIb IMPROVE-PAH trial for Pulmonary arterial hypertension (Combination therapy) in the second half of 2025
  • 13 Jun 2025 Inhibikase Therapeutics withdraws a phase IIb trial for Pulmonary arterial hypertension, prior to enrolment (PO) (NCT06643143)
  • 18 Dec 2024 Phase-III clinical trials in Chronic myeloid leukaemia in USA (PO) (Inhibikase Therapeutics pipeline, December 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top